Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors

NCT00831844 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00831844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00831844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
October 31, 2013
Enrollment
116 (actual)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

adult rhabdomyosarcoma, adult synovial sarcoma, childhood hepatoblastoma, childhood synovial sarcoma, neuroectodermal tumor, previously treated childhood rhabdomyosarcoma, recurrent adrenocortical carcinoma, recurrent adult soft tissue sarcoma, recurrent childhood liver cancer, recurrent childhood rhabdomyosarcoma, recurrent childhood soft tissue sarcoma, recurrent ewing sarcoma/peripheral primitive, recurrent neuroblastoma, recurrent osteosarcoma, recurrent retinoblastoma, recurrent wilms tumor and other childhood kidney tumors